Hereditary transthyretin amyloidosis overview

Area of Science:

• Genetics and Molecular Biology
• Cardiology
• Neurology

Background:

• Hereditary transthyretin amyloidosis (ATTRv) is a rare, autosomal dominant disorder.
• Caused by mutations in the transthyretin (TTR) gene, leading to unstable TTR tetramers.
• Amyloid deposits and toxic species cause multisystemic disease, primarily affecting the peripheral nervous system and heart.

Purpose of the Study:

• To review current knowledge on ATTRv amyloidosis.
• Covering pathogenesis, clinical manifestations, diagnosis, and treatment.
• Including presymptomatic testing and carrier management strategies.

Main Methods:

• Literature review of pathogenesis, clinical presentation, and diagnostic approaches.
• Analysis of current and emerging therapeutic strategies.
• Discussion of presymptomatic testing and carrier management.

Main Results:

• ATTRv amyloidosis results from TTR gene mutations causing amyloid fibril formation.
• Peripheral neuropathy and cardiomyopathy are key clinical features.
• Novel therapies are transforming disease management, necessitating timely diagnosis.

Conclusions:

• Understanding ATTRv pathogenesis is crucial for developing effective treatments.
• Early diagnosis and intervention are vital for improving patient outcomes.
• Presymptomatic testing and carrier management are essential for hereditary transthyretin amyloidosis.